About 16% of Medicare beneficiaries who were diagnosed with opioid addiction in 2020 received medication assisted treatment (MAT). Of the total 62.6 million beneficiaries in 2020, about 1.6% (nearly 1.06 million beneficiaries) were diagnosed with opioid addiction. In total 167,734 Medicare beneficiaries with diagnosed addiction received MAT with buprenorphine, methadone, or naltrexone. Less than half of those who received MAT also received behavioral therapy. Across the states, the share of Medicare beneficiaries diagnosed with opioid addiction in 2020 who received MAT ranged from 5% in Florida to 56% in Vermont. MAT receipt rates were lower for . . .
News Report |